Oral Retinol, Alone or Combined with Medical Photoprotection, in Patients with Actinic Keratosis: A Randomized, Open-Label, Prospective, Multicentric Study.
Marco Ardigò, Martina Burlando, Elena Campione, Gianluca Nazzaro, Giulio Foggi, Francesca Colombo, Stefano Alfano, Massimo Milani, Angelo V Marzano
{"title":"Oral Retinol, Alone or Combined with Medical Photoprotection, in Patients with Actinic Keratosis: A Randomized, Open-Label, Prospective, Multicentric Study.","authors":"Marco Ardigò, Martina Burlando, Elena Campione, Gianluca Nazzaro, Giulio Foggi, Francesca Colombo, Stefano Alfano, Massimo Milani, Angelo V Marzano","doi":"10.1007/s13555-026-01881-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Actinic keratosis (AK) is a chronic ultraviolet-induced condition with potential progression to squamous cell carcinoma. This study assessed the efficacy and tolerability of oral retinol, alone or combined with broad-spectrum medical photoprotection containing piroxicam, in patients with mild-to-moderate AK.</p><p><strong>Methods: </strong>In this multicenter, prospective, randomized, open-label study, 117 patients with up to six AK lesions were assigned to oral retinol 50,000 international units (IU)/day (group A), oral retinol plus medical photoprotection (group B), or standard photoprotection recommendations (group C). Treatment lasted 6 months, followed by 3 months of follow-up. Assessments were performed at baseline and at months 3, 6, and 9. The primary endpoint was change in Actinic Keratosis Area and Severity Index (AKASI). Secondary outcomes included global clinical efficacy, lesion clearance, tolerability, and exploratory line-field confocal optical coherence tomography findings.</p><p><strong>Results: </strong>All 117 patients were included in the intention-to-treat analysis, and 99 in the per-protocol analysis. AKASI scores decreased significantly in group A at month 6 by - 19.3% (mean difference (MD) 0.61, 95% confidence interval (CI) 0.11-1.11; p < 0.05) and at month 9 by - 22.5% (MD 0.71, 95% CI 0.18-1.25; p < 0.01). In group B, significant reductions were observed at all time points (T3: - 24.1%; MD 0.90, 95% CI 0.42-1.39; p < 0.0001; T6: - 34.9%; MD 1.31, 95% CI 0.86-1.76; p < 0.0001; T9: - 38.8%; MD 1.45, 95% CI 0.95-1.95; p < 0.0001). No significant changes occurred in group C. Reductions were earlier and greater with the combined strategy. Global clinical efficacy was rated good or very good in 69% of patients in group A and 88% in group B, while lesion clearance rates were 56% and 82%, respectively. Tolerability was generally good, and no treatment-related adverse events were formally recorded. In the imaging substudy, significant reductions in epidermal and stratum corneum thickness occurred only in group B.</p><p><strong>Conclusions: </strong>Oral retinol combined with medical photoprotection was associated with earlier and greater improvements than oral retinol alone or standard photoprotection recommendations. These findings support further controlled studies to confirm efficacy and clarify the contribution of each intervention.</p><p><strong>Trial registration: </strong>Trial registration number ISRCTN42565762, retrospectively registered on 18 May 2026.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-026-01881-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Actinic keratosis (AK) is a chronic ultraviolet-induced condition with potential progression to squamous cell carcinoma. This study assessed the efficacy and tolerability of oral retinol, alone or combined with broad-spectrum medical photoprotection containing piroxicam, in patients with mild-to-moderate AK.
Methods: In this multicenter, prospective, randomized, open-label study, 117 patients with up to six AK lesions were assigned to oral retinol 50,000 international units (IU)/day (group A), oral retinol plus medical photoprotection (group B), or standard photoprotection recommendations (group C). Treatment lasted 6 months, followed by 3 months of follow-up. Assessments were performed at baseline and at months 3, 6, and 9. The primary endpoint was change in Actinic Keratosis Area and Severity Index (AKASI). Secondary outcomes included global clinical efficacy, lesion clearance, tolerability, and exploratory line-field confocal optical coherence tomography findings.
Results: All 117 patients were included in the intention-to-treat analysis, and 99 in the per-protocol analysis. AKASI scores decreased significantly in group A at month 6 by - 19.3% (mean difference (MD) 0.61, 95% confidence interval (CI) 0.11-1.11; p < 0.05) and at month 9 by - 22.5% (MD 0.71, 95% CI 0.18-1.25; p < 0.01). In group B, significant reductions were observed at all time points (T3: - 24.1%; MD 0.90, 95% CI 0.42-1.39; p < 0.0001; T6: - 34.9%; MD 1.31, 95% CI 0.86-1.76; p < 0.0001; T9: - 38.8%; MD 1.45, 95% CI 0.95-1.95; p < 0.0001). No significant changes occurred in group C. Reductions were earlier and greater with the combined strategy. Global clinical efficacy was rated good or very good in 69% of patients in group A and 88% in group B, while lesion clearance rates were 56% and 82%, respectively. Tolerability was generally good, and no treatment-related adverse events were formally recorded. In the imaging substudy, significant reductions in epidermal and stratum corneum thickness occurred only in group B.
Conclusions: Oral retinol combined with medical photoprotection was associated with earlier and greater improvements than oral retinol alone or standard photoprotection recommendations. These findings support further controlled studies to confirm efficacy and clarify the contribution of each intervention.
Trial registration: Trial registration number ISRCTN42565762, retrospectively registered on 18 May 2026.
期刊介绍：
Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
